Nirav Shah, MD, discusses findings from an interim analysis of the phase 2 DALY II trial, which is the first pivotal trial evaluating tandem CD20-CD19 directed CAR T-cell product, zamtocabtagene autoleucel, for patients with relapsed/refractory DLBCL.
Join us for upcoming webinars associated with AACR IO: Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy
The American Society for Transplantation and Cellular Therapy is an international professional membership association of more than 3,900 physicians, investigators and other health care professionals…
Nature Reviews Clinical Oncology – Accumulating evidence indicates that NUT carcinoma, a highly aggressive malignancy driven by NUTM1 fusions, is a rare form of squamous…
At today’s Senate Health, Education, Labor, and Pensions Committee hearing, nominee for Secretary of the Department of Health and Human Services Robert F. Kennedy (RFK)…
Austin D. Williams, MD, MSEd, FACS, was recently named a Presidential Scholar by the Society of Surgical Oncology.
Imetelstat is an oligonucleotide telomerase inhibitor recently approved by the US Food and Drug Administration for adults with lower-risk myelodysplasia wh
FDA approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic hormone receptor-positive, HER2-low (IHC 1+ or…
Panelists discuss how myelofibrosis progresses from its molecular and genetic origins through various clinical manifestations, ultimately informing the development of targeted therapeutic approaches for this…
Results from the ZN-c3-001, MAMMOTH, and DENALI trials demonstrated meaningful ORRs with azenosertib in platinum-resistant ovarian cancer.
